Work in the lab of PS has been supported by Canada Research Chairs, Canada Foundation for Innovation, Alberta Prion Research Institute, Alberta InnovatesNovartis, MS Society of Canada, National MS Society, National Institutes of Health, Canadian Institutes for Health Research, the Hopewell M.I.N.D prize, Alzheimers Society, Barford Foundation, Krembil Foundation, and generous philanthropists
GLP-3 + Cagrilintide research peptide blend is not approved for human consumption, medical use, or therapeutic application
When calorie intake drops, it is common to notice lower energy, more fatigue, and reduced motivation
Twice-daily dosing: Best for acute injuries Maintains more consistent peptide levels Often used for the first 12 weeks Morning and evening Total daily dose can be split between injections Once-daily dosing: Suitable for chronic conditions More convenient for long-term protocols Often used after the early healing phase Morning dosing is often preferred Full daily dose in a single injection Timing factors: Can be administered any time of day Consistent timing improves adherence No specific relationship to meals needed No specific timing relative to exercise needed Many researchers prefer morning dosing for convenience Localized vs
